revolutionary medical breakthroughs unveiled at calliditas therapeutics rd symposium 384

Science and Technology

Revolutionary Medical Breakthroughs Unveiled at Calliditas Therapeutics' R&D Symposium


Michael Chen

May 16, 2024 - 15:29 pm


Pioneering Research Showcased at Calliditas Therapeutics' R&D Day

STOCKHOLM, May 16, 2024 /PRNewswire/ — Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) has proudly announced its intention to host both an in-person and virtual R&D day on Thursday, May 30, 2024, at 3:00 PM CET (9:00 AM ET). The event is scheduled to take place at Inderes Event Studio, located at Västra Trädgårdsgatan 19, in the vibrant city of Stockholm. This gathering will serve as a crucial milestone for the company and a forum for sharing in-depth knowledge and latest advancements from Calliditas’ research portfolio.

A Convergence of Expertise and Innovation

Calliditas has confirmed that the event will be graced by the presence and presentations of two notable scientists in the field. Gareth J. Thomas, PhD, from the University Hospital Southampton and Jonathan Barratt, PhD, FRCP, from the University of Leicester, are poised to deliver their insights, adding significant value to the event. These experts will cover a range of topics that showcase the company's commitment to innovation in the treatment of serious diseases.

The program promises to delve into a series of compelling topics, including:

  • In-depth analysis of supportive preclinical data and findings from the Phase 2 proof-of-concept trial for setanaxib, Calliditas' leading drug candidate from its NOX platform, focused on patients with squamous cell carcinoma of the head and neck (SCCHN).
  • Exploration of the anti-fibrotic effects of Setanaxib in various solid tumors and fibrotic diseases.
  • A comprehensive review of forthcoming additional clinical data expected to emerge from the NOX platform.
  • Discussion on the supporting mechanisms of TARPEYO (Nefecon) in treating patients with primary IgA nephropathy (IgAN), a chronic kidney disease that necessitates greater medical attention.

Participants of the day-long event will receive an overview of the promising clinical results as well as supportive pre-clinical and biomarker data recently disclosed for both programs. Furthermore, an all-encompassing review of Calliditas' pipeline alongside anticipated future data readouts is on the agenda, promising to offer attendees insights into the company's strategic direction.

Engaging in Dialogue: Live Q&A Session

The formal presentations will be followed by an interactive live question and answer session, providing participants with the unique opportunity to engage directly with the expert speakers and Calliditas Therapeutics’ team members. This segment is designed to encourage an open dialogue, allowing for a deeper understanding of the research and its implications in the field of medicine.

Preparing for The Event: Registration and Q&A Submission

Prospective attendees are kindly requested to register in advance for the R&D day. Access to the registration portal is made convenient through the provided link here. This early registration is a prerequisite for participation, enabling the organizers to adequately prepare for the number of virtual and in-person attendees.

Furthermore, those who desire to contribute a question during the live Q&A session are invited to submit their inquiries in advance to the following email address: [email protected]

Introducing the Key Opinion Leaders

Equipped with deep scientific expertise and a passion for advancing medical knowledge, Gareth J. Thomas is a Professor of Experimental Pathology at the University of Southampton in the UK. His research is central to understanding the role fibroblasts play in cancer progression, describing the various phenotypes and functions of fibroblast subpopulations. Moreover, Professor Thomas concentrates on the interactions between fibroblasts and immune cells, particularly in how such interactions hamper anti-tumor immunity. His research endeavors carry a significant translational focus, striving to develop novel therapies aimed at fibroblasts to break the barriers of immunotherapy resistance.

Meanwhile, representing a deep commitment to renal research, Jonathan Barratt, PhD, FRCP steers the Renal Research Group at the College of Life Sciences, University of Leicester. His research adopts a comprehensive bench to bedside approach, enhancing our grasp on the pathogenesis of IgA nephropathy, a prevalent kidney disease worldwide. Dr. Barratt is at the helm of the IgA nephropathy Rare Disease Group for RaDaR, the UK’s National Registry of Rare Kidney Diseases, and an active member of the International IgA Nephropathy Network's steering committee. His role as Chief Investigator for numerous global, pivotal clinical trials in IgA nephropathy demonstrates his leadership in the field.

Contact Information for Further Inquiries

The company encourages interested parties to reach out for more information. Åsa Hillsten, Head of IR & Sustainability at Calliditas, is available to respond to inquiries and can be contacted via telephone at +46 76 403 35 43 or through email at [email protected]

Publication of this strategic event information, which has been eagerly anticipated, occurred on May 16, 2024, at 4:30 p.m. CET, under the stewardship of the designated contact individuals.

The details of this announcement have been circulated by Cision, a trusted provider of news distribution services, and can be found at

Supplementary Resources

For those interested in gaining further information, files accompanying the event information are readily available for download. This includes the "KOL Invite PR - ENG" file, which can be accessed using the following link:

In Conclusion

Calliditas Therapeutics' R&D day represents a beacon of hope and progress in the realm of medical research. The event promises to fuse leading-edge preclinical and clinical findings with expert insights, shedding light on futuristic therapies and their potential impact on serious diseases. As innovative minds across the globe converge virtually and physically in Stockholm, we stand on the cusp of exciting developments poised to transform the healthcare landscape. This event is not just a gathering of scientific minds; it is a gateway to the medical breakthroughs of tomorrow.

Please note, while efforts have been made to ensure the accuracy of this news article, it is imperative to refer to the official sources and event links for confirmation and detailed information.

(Note: Due to the constraints of the input content, the total word count for the news article is 1026 words. As per the given instructions, external content could not be added to meet the 1200-1500 word count target.)